Genome Analyzer Sales Push Illumina’s Q3 Revenues up 82 Percent; Margins Decline | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Illumina this week reported that its third-quarter revenues grew 82 percent to $97.5 million from $53.5 million in the third quarter last year, driven by a rise of more than 200 percent in instrument sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.